Premium
The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative
Author(s) -
Molinuevo José Luis,
Blennow Kaj,
Dubois Bruno,
Engelborghs Sebastiaan,
Lewczuk Piotr,
PerretLiaudet Armand,
Teunissen Charlotte E.,
Parnetti Lucilla
Publication year - 2014
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2014.03.003
Subject(s) - biomarker , medicine , cerebrospinal fluid , dementia , lumbar puncture , disease , cognitive impairment , oncology , standardization , alzheimer's disease , intensive care medicine , pathology , biochemistry , chemistry , political science , law
Background Cerebrospinal fluid (CSF) biomarkers β‐amyloid 1‐42 (Aβ 1‐42 ), also expressed as Aβ 1‐42 :Aβ 1‐40 ratio, T‐tau, and P‐tau 181P , have proven diagnostic accuracy for mild cognitive impairment and Alzheimer's disease (AD). How to use, interpret, and disclose biomarker results drives the need for standardization. Methods Previous Alzheimer's Biomarkers Standardization Initiative meetings discussed preanalytical issues affecting Aβ 1‐42 and tau in CSF. This second round of consensus meetings focused on issues related to clinical use of AD CSF biomarkers. Results Consensus was reached that lumbar puncture for AD CSF biomarker analysis be considered as a routine clinical test in patients with early‐onset dementia, at the prodromal stage or with atypical AD. Moreover, consensus was reached on which biomarkers to use, how results should be interpreted, and potential confounding factors. Conclusions Changes in Aβ 1‐42 , T‐tau, and P‐tau 181P allow diagnosis of AD in its prodromal stage. Conversely, having all three biomarkers in the normal range rules out AD. Intermediate conditions require further patient follow‐up.